GlassScriptPhysician profile
Han Dang
NPI 1811929508
$14,091.71
in general payments reported to CMS, 2019-2025
31 companies · $2,326 in 2025
The $2,326 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $1,465 · 2021: $1,945 · 2022: $4,083 · 2023: $1,241 · 2024: $1,971 · 2025: $2,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,525 · Travel and Lodging: $13.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,525.16 |
| Travel and Lodging | $13.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,141.59 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $1,504.65 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $1,194.06 | 2020-2025 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $924.39 | 2019-2025 | Vafseo, Auryxia |
| Amgen INC. | $886.16 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $788.18 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $731.66 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $699.26 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $684.60 | 2019-2025 | Jynarque, Voyxact |
| Ani Pharmaceuticals, INC. | $507.89 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $494.48 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $349.42 | 2022-2025 | |
| Glaxosmithkline, LLC. | $278.93 | 2022-2025 | Jesduvroq, Benlysta |
| Novartis Pharmaceuticals Corporation | $277.72 | 2023-2025 | |
| Outset Medical INC | $256.09 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $238.18 | 2019 | |
| Ardelyx, INC. | $176.88 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $173.40 | 2019-2024 | Velphoro |
| Aurinia Pharma U.S., INC. | $165.26 | 2022-2024 | Lupkynis |
| Lilly USA, LLC | $107.61 | 2023-2025 | Jardiance, Mounjaro |
| Scpharmaceuticals INC. | $103.83 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.01 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $77.76 | 2024-2025 | Ozempic, Rybelsus |
| Apellis Pharmaceuticals, INC. | $64.88 | 2025 | Empaveli |
| Cook Medical LLC | $51.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.83 | 2023 | Gattex |
| Abbott Laboratories | $29.56 | 2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $20.48 | 2020 | |
| Genzyme Corporation | $15.57 | 2019 | |
| Optinose US, INC. | $12.07 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Han Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.